Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use

Table 2 Cardiovascular safety markers, part I

Variable	T1	T2	T3	Time*group	Timegroupgender
SBP (mm Hg)
PLA	117 ± 15	116 ± 12	115 ± 13	Time p = 0.45	GTGe p = 0.73
LD	116 ± 9	115 ± 8	116 ± 6	G*T p = 0.12
HD	118 ± 15	124 ± 12	122 ± 13	G*T p = 0.12
DBP (mm Hg)
PLA	69 ± 9	68 ± 9	68 ± 9	Time p = 0.58	GTGe p = 0.89
LD	70 ± 7	67 ± 8	71 ± 8	G*T p = 0.53
HD	70 ± 8	68 ± 8	73 ± 8	G*T p = 0.53
Heart rate (beats/min)
PLA	60 ± 10	64 ± 8	63 ± 10	Time p = 0.032	GTGe p = 0.85
LD	60 ± 15	59 ± 10^a	63 ± 12^a	G*T p = 0.35
HD	59 ± 12	63 ± 10	64 ± 13	G*T p = 0.35
Vent Rate (breath/min)
PLA	60 ± 9	61 ± 10	62 ± 8	Time p = 0.43	GTGe p = 0.67
LD	57 ± 13	59 ± 11	60 ± 13	G*T p = 0.10
HD	63 ± 12	59 ± 11	61 ± 11	G*T p = 0.10

Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
Superscript letters, different letters are significantly different at a given time point (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed

ISSN: 1550-2783